Advertisement

Behavioral Psychopharmacology: A New Psychiatric Subspecialty

  • Robert Sovner
Part of the Disorders of Human Learning, Behavior, and Communication book series (HUMAN LEARNING)

Abstract

After years of being viewed with distrust and challenged with medicolegal initiative (see reviews by: Aman, 1985; Aman & Singh, 1986; Plotkin & Gill, 1979; and Sprague, 1982), there has been a resurgence of interest in the use of psychotropic medications to treat behavioral and emotional disturbances in persons with developmental disabilities (Aman, 1983). This interest has been stimulated, in large part, by a growing awareness that the mentally retarded exhibit the full spectrum of mental disorders and can be treated with all types of psychiatric therapies (Corbett, 1979; Gostason, 1985; Lund, 1985; Reid, 1972a, 1972b; Reid, 1982; Sovner & Hurley, 1983; Wright, 1982).

Keywords

Mental Retardation Antipsychotic Drug Maladaptive Behavior Mental Deficiency Opiate Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aman, M.G. (1983). Psychoactive drugs in mental retardation. In J.L. Matson & F. Andrasik(Eds.), Treatment issues and innovations in mental retardation. New York: Plenum Press.Google Scholar
  2. Aman, M.G. (1985). Drugs in mental retardation: Treatment or tragedy? Australian and New Zealand Journal of Developmental Disorders, 10, 215–226.Google Scholar
  3. Aman, M.G., & Singh, N.N. (1980). The usefulness of thioridazine for treating childhood disorders—Fact or folklore? American Journal of Mental Deficiency, 83, 331–338.Google Scholar
  4. Aman, M.G., & Singh, N.N. (1986). A critical appraisal of recent drug research in mental retardation: The Cold water studies. Journal of Mental Deficiency Research, 30, 203–216.PubMedGoogle Scholar
  5. Aman, M.G., & White, A.J. (1986). Measures of drug change in mental retardation. Advances in Learning and Behavioral Disabilities, 5, 157–203.Google Scholar
  6. Archer, J.D. (1984). The FDA does not approve uses of drugs (Editorial). JAMA, 252, 1054–1055.PubMedCrossRefGoogle Scholar
  7. Ballinger, J.C., & Post, R.M. (1980). Carbamazepine in manic-depressive illness. A new treatment. American Journal of Psychiatry, 137, 782–790.Google Scholar
  8. Ballinger, B.R., & Reid, A.H. (1977). Psychiatric disorder in an adult training centre and a hospital for the mentally handicapped. Psychological Medicine, 7, 525–528.PubMedCrossRefGoogle Scholar
  9. Beckwith, B.E., Couk, D.I., & Schumacher, K. (1986). Failure of naloxone to reduce self-injurious behavior in two developmentally disabled females. Applied Research in Mental Retardation, 7, 183–188.PubMedCrossRefGoogle Scholar
  10. Chouinard, G., Bradwejn, J., Annable, L., Jones, B.D., & Ross-Chouinard, A. (1984). Withdrawal symptoms after long-term treatment with low-potency neuroleptics. Journal of Clinical Psychiatry, 45, 500–502.PubMedGoogle Scholar
  11. Corbett, J. (1979). Psychiatric morbidity and mental retardation. In F.E. James & R.P Snaith (Eds.), Psychiatric illness and mental handicap (pp. 11–25). London: Gaskell Press.Google Scholar
  12. Dale, P.G. (1980). Lithium therapy in aggressive mentally subnormal patients. British Journal of Psychiatry, 137, 469–474.PubMedCrossRefGoogle Scholar
  13. Eyman, R.K., & Call, T. (1977). Maladaptive behavior and community placement of mentally retarded persons. American Journal of Mental Deficiency, 82, 137–144.PubMedGoogle Scholar
  14. Eyman, R.K., Moore, B.C., Capes, L., & Zachofsky, T. (1970). Maladaptive behavior of institutionalized retardates with seizures. American Journal of Mental Deficiency, 74, 651–659.PubMedGoogle Scholar
  15. Gardos, G., Cole, J.O., & Tarsy, D. (1978). Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry, 135, 1321–1324.PubMedGoogle Scholar
  16. Gillman, M.A., & Sandyk, R. (1985). Opiatergic and dopaminergic function and Lesch-Nyhan syndrome. American Journal of Psychiatry, 142, 1226.PubMedGoogle Scholar
  17. Gostason, R. (1985). Psychiatric illness among the mentally retarded. Acta Psychiatrica Scandinavica (Suppl. 318), 71, 1–117.CrossRefGoogle Scholar
  18. Gualtieri, C.T., Quade, D., Hicks, R.E., Mayo, J.P., & Schroeder, S.R. (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. American Journal of Psychiatry, 141, 20–23.PubMedGoogle Scholar
  19. Hucker, S.J., Day, K.A., George, S., & Roth, M. (1979). Psychosis in mentally handicapped adults. In F.E. James & R.P. Snaith (Eds.), Psychiatric illness and mental handicap (pp. 27–35). London: Gaskell Press.Google Scholar
  20. Kanjilal, D.C. (1977). An evaluation of Tegretol in adults with epilepsy. In Tegretol in Epilepsy Proceedings of an International Meeting (pp. 55–57). London: Geigy Pharmaceuticals.Google Scholar
  21. Kapp, M.B. (1981). Prescribing approved drugs for nonapproved uses: Physicians’ disclosure obligations to their patients. Law Medicine & Healthcare, 20–23.Google Scholar
  22. Lerer, B. (1985). Alternative therapies for bipolar disorder. Journal of Clinical Psychiatry, 46, 309–316.PubMedGoogle Scholar
  23. Lion, J.R., Hill, J., & Madden, DJ. (1975). Lithium carbonate and aggression: A case report. Diseases of the Nervous System, 36, 557–558.PubMedGoogle Scholar
  24. Lund, J. (1985). The prevalence of psychiatric morbidity in mentally retarded adults. Acta Psychiatrica Scandinavica, 72, 563–570.PubMedCrossRefGoogle Scholar
  25. Matson, J.L. (1986). Self-injury and its relationship to diagnostic schemes in psycho-pathology. Applied Research in Mental Retardation, 7, 223–227.PubMedCrossRefGoogle Scholar
  26. McHugh, P.R., & Slavney, P.R. (1983). The perspective of psychiatry. Baltimore, MD: The Johns Hopkins Press.Google Scholar
  27. Menolascino, F.J. (1972). Primitive, atypical, and abnormal-psychotic behavior in institutionalized mentally retarded children. Journal of Autism and Childhood Schizophrenia, 3, 49–64.CrossRefGoogle Scholar
  28. Menolascino, F.J. (1983). Overview. Bridging the gap between mental retardation and mental illness. In F.J. Menolascino & B.M. McCann (Eds.), Mental health and mental retardation. Baltimore, MD: University Park Press.Google Scholar
  29. Mikkelson, E.J. (1986). Low-dose haloperidol for stereotypic self-injurious behavior in the mentally retarded. New England Journal of Medicine, 315, 398–399.Google Scholar
  30. Paniagua, C., & DeFazio, A. (1983). Psychodynamics of the mildly retarded and borderline intelligence adult. Psychiatric Quarterly, 242–252.Google Scholar
  31. Plotkin, R., & Gill, K.R. (1979). Invisible manacles: Drugging mentally retarded people. Stanford Law Review, 31, 637–678.PubMedCrossRefGoogle Scholar
  32. Rapport, M.D., Sonis, W.A., Fialkov, M.J., Matson, J.L., & Kazdin, A.E. (1983). Carba-mazepine and behavior therapy for aggressive behavior. Behavior Modification, 7, 255–265.PubMedCrossRefGoogle Scholar
  33. Ratey, J.J., Mikkelson, E.J., Smith, G.B., Upadhyaya, A., Zuckerman, H.S., Martell, D, Sorgi, P., Polakoff, S., & Bemporad, J. (1986). ß-blockers in the severely and profoundly mentally retarded. Journal of Clinical Psychopharmacology, 6, 103–107.PubMedCrossRefGoogle Scholar
  34. Reid, A.H. (1972a). Psychoses in adult mental defectives: I. Manic depressive psychosis. British Journal of Psychiatry, 120, 205–212.PubMedCrossRefGoogle Scholar
  35. Reid, A.H., (1972b). Psychoses in adult mental defectives: II. Schizophrenic and paranoid psychoses. British Journal of Psychiatry, 120, 213–218.PubMedCrossRefGoogle Scholar
  36. Reid, A.H. (1982). The psychiatry of mental handicap. Oxford: Blackwell Scientific Publications.Google Scholar
  37. Reid, A.H., Ballinger, B.R., Heather, B.B., & Melvin, S J. (1984). The natural history of behavioral symptoms among severely and profoundly mentally retarded patients. British Journal of Psychiatry, 145, 289–293.PubMedCrossRefGoogle Scholar
  38. Reid, A.H., Naylor, G.J., & Kay, D.S.G. (1981). A double-blind, placebo controlled, crossover trial of carbamazepine in overactive, severely mentally handicapped patients. Psychological Medicine, 11, 109–113.PubMedCrossRefGoogle Scholar
  39. Richardson, J.S., & Zaleski, W.A. (1986). Endogenous opiates and self-mutilation. American Journal of Psychiatry, 143, 938–939.PubMedGoogle Scholar
  40. Sandman, C.A., Datta, P.C., Barron, J., Hoehler, F.K., Williams, C, Swanson, J.M. (1983). Naxolone attentuates self-abusive behavior in developmentally disabled clients. Applied Research in Mental Retardation, 4, 5–11.PubMedCrossRefGoogle Scholar
  41. Sandyk, C.A., Datta, P.C., Barron, I, Hoehler, F.K., Williams, C, & Swanson, J.M. (1983). Naloxone attentuates self-abusive behavior in developmentally disabled clients. Applied Research in Mental Retardation, 4, 5–11.CrossRefGoogle Scholar
  42. Sovner, R. (1986). Limiting factors in the use of DSM-III criteria with mentally ill—mentally retarded persons. Psychopharmacology Bulletin, 22, 1055–1059.PubMedGoogle Scholar
  43. Sovner, R., & DiMascio, A. (1978). Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In M. A. Lipton, A. DiMascio, & K.F. Killam (Eds.), Psychopharmacology: A generation of progress. New York: Raven Press.Google Scholar
  44. Sovner, R., & Hurley, A.D. (1981). The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Disorders, 169, 191–195.CrossRefGoogle Scholar
  45. Sovner, R., & Hurley, A.D. (1982). Psychotropic drug side effects presenting as behavior disorders. Psychiatric Aspects of Mental Retardation, 1, 45–48.Google Scholar
  46. Sovner, R., & Hurley, A.D. (1983). Do the mentally retarded suffer from affective illness? Archives of General Psychiatry, 40, 61–67.PubMedGoogle Scholar
  47. Sovner, R., & Hurley, A.D. (1986). Managing aggressive behavior: A psychiatric approach. Psychiatric Aspects of Mental Retardation, 5, 16–21.Google Scholar
  48. Sprague, R. (1982). Litigation, legislation, and regulations. In S.E. Breuning & A.D. Poling (Eds.), Drugs and mental retardation (pp. 377–414). Springfield, IL: Charles C Thomas.Google Scholar
  49. Sprague, R.L., & Werry, J.S. (1971). Methodology of psychopharmacological studies with the retarded. In N.R. Ellis (Ed.), International review of research in mental retardation (Vol. 5). New York: Academic Press.Google Scholar
  50. Tyrer, S.P., Walsh, A., Edwards, D.E., Berney, T.P, & Stephens, D.A. (1984). Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 8, 751–755.CrossRefGoogle Scholar
  51. Worrall, E.P., Moody, J.P., & Naylor, G.J. (1975). Lithium in non-manic depressives: Antiaggressive effect and red blood cell lithium values. British Journal of Psychiatry, 126, 464–468.PubMedCrossRefGoogle Scholar
  52. Wright, E.C. (1982). The presentation of mental illness in mentally retarded adults. British Journal of Psychiatry, 141, 496–502.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Robert Sovner

There are no affiliations available

Personalised recommendations